[Click eStock] "GenCurix, Breast Cancer Prognosis Diagnostic Product Sales to Accelerate This Year"

[Asia Economy Reporter Hyunseok Yoo] Leading Investment & Securities analyzed on the 25th that GenesWell BCT's breast cancer prognosis diagnosis sales will become full-scale this year. No investment opinion or target price was presented.

GenesWell BCT was established in 2011 and develops medical devices for cancer prognosis diagnosis, companion diagnostics, and early diagnosis. Its main products include the breast cancer prognosis diagnosis kit GenesWell BCT and companion diagnostic kits for lung cancer and colorectal cancer.

Seungtaek Oh, a researcher at Leading Investment & Securities, said, "GenesWell BCT's prognosis diagnosis product, the GenesWell BCT kit, is priced below 3 million KRW compared to Genomic Health's Oncotype DX, which holds a global exclusive position and costs 4,500 USD (about 5 million KRW)." He added, "If actual expense insurance is applied, the patient's burden will drop to about one-tenth compared to competing products, giving it price competitiveness."

He continued, "Although Oncotype DX is currently the most widely used breast cancer prognosis test in Korea, verification for Asian ethnicities is insufficient. GenesWell BCT's product was the first in the world to verify efficacy in clinical trials targeting Asians, and discussions are underway to introduce it to major domestic hospitals, aiming to enter the top 70 hospitals in Korea within this year." He added, "Some sales will begin from the second quarter, and full-scale sales expansion is expected in the second half."

Additionally, GenesWell BCT has developed a kit that analyzes cancer patients' genetic information to diagnose whether a specific targeted anticancer drug is suitable for the patient's treatment. He evaluated, "Early diagnosis products for colorectal cancer and liver cancer target the general public, so they have a larger market potential. Clinical trials targeting the US market are planned, and since diagnosis is done by collecting blood instead of the existing stool collection method, patient convenience is improved, which will help increase market share."